BG64196B1 - 3-пиридил енантиомери и използването им като аналгетици - Google Patents

3-пиридил енантиомери и използването им като аналгетици Download PDF

Info

Publication number
BG64196B1
BG64196B1 BG103556A BG10355699A BG64196B1 BG 64196 B1 BG64196 B1 BG 64196B1 BG 103556 A BG103556 A BG 103556A BG 10355699 A BG10355699 A BG 10355699A BG 64196 B1 BG64196 B1 BG 64196B1
Authority
BG
Bulgaria
Prior art keywords
compound
ethenyl
group
formula
azetidine
Prior art date
Application number
BG103556A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103556A (en
Inventor
Mark W. Holladay
Stephen P. Arneric
Hao Bai
Michael J. Dart
Nan-Horng Lin
John K. Lynch
Yat S. Or
Keith B. Ryther
James P. Sullivan
James T. Wasicak
Paul P. Ehrich
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG103556A publication Critical patent/BG103556A/xx
Publication of BG64196B1 publication Critical patent/BG64196B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG103556A 1996-12-10 1999-07-06 3-пиридил енантиомери и използването им като аналгетици BG64196B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3232196P 1996-12-10 1996-12-10
US76327896A 1996-12-10 1996-12-10
PCT/US1997/022811 WO1998025920A1 (en) 1996-12-10 1997-12-10 3-pyridyl enantiomers and their use as analgesics

Publications (2)

Publication Number Publication Date
BG103556A BG103556A (en) 2000-06-30
BG64196B1 true BG64196B1 (bg) 2004-04-30

Family

ID=26708255

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103556A BG64196B1 (bg) 1996-12-10 1999-07-06 3-пиридил енантиомери и използването им като аналгетици

Country Status (21)

Country Link
EP (1) EP0950057B1 (pt)
JP (2) JP4272261B2 (pt)
KR (2) KR100422995B1 (pt)
CN (1) CN1125064C (pt)
AT (1) ATE227717T1 (pt)
AU (1) AU733881B2 (pt)
BG (1) BG64196B1 (pt)
BR (1) BR9714677A (pt)
CA (2) CA2273917C (pt)
DE (1) DE69717148T2 (pt)
DK (1) DK0950057T3 (pt)
ES (1) ES2189003T3 (pt)
HU (1) HUP0001110A3 (pt)
IL (1) IL130083A0 (pt)
NO (1) NO992705L (pt)
NZ (1) NZ335810A (pt)
PL (1) PL333920A1 (pt)
PT (1) PT950057E (pt)
SK (1) SK75999A3 (pt)
TR (1) TR199901904T2 (pt)
WO (1) WO1998025920A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510619A (ja) 1998-04-02 2002-04-09 アール・ジェイ・レイノルズ・タバコ・カンパニー 薬剤組成物及びその使用法
US6054451A (en) * 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6103911A (en) * 1999-06-15 2000-08-15 Abbott Laboratories Process for reduction of (2R)-4-oxoazetidinone-2-carboxylic acid
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2006504634A (ja) * 2002-05-15 2006-02-09 アボット・ラボラトリーズ 神経障害性疼痛の治療
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
CA2631128A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
TW200800020A (en) * 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
JP4939192B2 (ja) * 2006-12-05 2012-05-23 ユニ・チャーム株式会社 不織布、不織布の製造方法及び吸収性物品
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
CN102216289A (zh) 2008-10-14 2011-10-12 塞扣吉尼克斯公司 烟碱乙酰胆碱受体配体及其用途
US8474529B2 (en) * 2009-04-09 2013-07-02 Regency Technologies Llc Control of concentric tubing direction
AR075988A1 (es) * 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
RU2014103098A (ru) 2011-06-30 2015-08-10 Торэй Индастриз, Инк. Противозудный агент
CA2944179A1 (en) * 2013-03-27 2014-10-02 Georgetown University 2-halo-5-alkynyl-pyridyl nicotinic ligands
CA3066361A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
US11511103B2 (en) 2017-11-13 2022-11-29 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
CN112004563B (zh) 2018-02-01 2024-08-06 施菲姆德控股有限责任公司 血管内血泵以及使用和制造方法
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301702D0 (en) * 1983-01-21 1983-02-23 Shell Int Research Azetidine compounds
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

Also Published As

Publication number Publication date
KR20000069399A (ko) 2000-11-25
HUP0001110A2 (hu) 2001-04-28
NO992705D0 (no) 1999-06-03
SK75999A3 (en) 2000-05-16
DE69717148T2 (de) 2003-10-02
KR20040004476A (ko) 2004-01-13
DE69717148D1 (de) 2002-12-19
JP5364872B2 (ja) 2013-12-11
CA2698384A1 (en) 1998-06-18
NO992705L (no) 1999-08-03
TR199901904T2 (xx) 1999-10-21
JP4272261B2 (ja) 2009-06-03
NZ335810A (en) 2001-03-30
ES2189003T3 (es) 2003-07-01
CA2273917A1 (en) 1998-06-18
JP2001504857A (ja) 2001-04-10
BG103556A (en) 2000-06-30
KR100422995B1 (ko) 2004-03-12
PT950057E (pt) 2003-04-30
CN1245496A (zh) 2000-02-23
HUP0001110A3 (en) 2002-04-29
AU5601098A (en) 1998-07-03
CA2273917C (en) 2010-05-25
EP0950057B1 (en) 2002-11-13
BR9714677A (pt) 2000-10-03
PL333920A1 (en) 2000-01-31
EP0950057A1 (en) 1999-10-20
IL130083A0 (en) 2000-02-29
KR100472154B1 (ko) 2005-02-21
CN1125064C (zh) 2003-10-22
WO1998025920A1 (en) 1998-06-18
DK0950057T3 (da) 2003-03-10
CA2698384C (en) 2012-05-01
ATE227717T1 (de) 2002-11-15
JP2009143924A (ja) 2009-07-02
AU733881B2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
JP5364872B2 (ja) ３−ピリジルエナンチオマーおよび鎮痛薬としてのその使用
EP0663912B1 (en) Heterocyclic ether compounds that enhance cognitive function
JP4206212B2 (ja) キヌクリジン化合物およびそれを有効成分として含有する医薬
EP1107965B1 (en) Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
JP4489940B2 (ja) 化学的シナプス伝達制御において有用な複素環エーテルおよびチオエーテル化合物
US5472958A (en) 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
EP1736465A1 (en) Aniline derivatives
JPH06329669A (ja) 置換モノ−およびビピリジルメチルピリドン類
US6001849A (en) Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission
US20070179172A1 (en) Positive modulators of nicotinic acetylcholine receptors
US6133253A (en) 3-Pyridyl enantiomers and their use as analgesics
CA3226724A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
JP2013515031A (ja) Ｈｃｎ遮断薬としてのアミノ−ヘテロアリール誘導体
MXPA99005369A (en) 3-pyridyl enantiomers and their use as analgesics
CZ204899A3 (cs) 3-Pyridylové enantiomery a jejich použití jako analgetik
US6656958B2 (en) Substituted pyridine compounds useful for controlling chemical synaptic transmission
TW202400578A (zh) 新穎的化合物及其用於抑制檢查點激酶２的用途
WO2024069448A1 (en) Substituted 1-arylaminocarbonyl-1'-heteroaryl compounds, substituted 1-heteroarylaminocarbonyl-1'-heteroaryl compounds and methods using same
US20010034357A1 (en) Substituted pyridine compounds useful for controlling chemical synaptic transmission